logo
Windsurf Launches SWE-1: A Frontier AI Model Family Built for the Full Software Engineering Lifecycle

Windsurf Launches SWE-1: A Frontier AI Model Family Built for the Full Software Engineering Lifecycle

Business Wire15-05-2025

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Windsurf, the company transforming how software is built, today announced the launch of SWE-1, its first family of proprietary AI models designed to accelerate the entire software engineering process, not just code generation. The SWE-1 family includes three models optimized for different workflows and user tiers, and marks Windsurf's entry into frontier model development with performance competitive to foundational models for software-relevant tasks.
'Writing code is only a fraction of what engineers do,' said Varun Mohan, CEO and co-founder of Windsurf. 'To truly accelerate software development by 99%, we had to move beyond 'coding-capable' models and build software engineering-native models. SWE-1 is our first step in that direction, building a foundation for the future state.'
Meet the SWE-1 Family:
SWE-1: Windsurf's full-size model, built for advanced reasoning and tool use. Available for unlimited use to all paid users.
SWE-1-lite: A smaller but powerful model that replaces Cascade Base, now available for unlimited use to all users, free and paid.
SWE-1-mini: A lightweight model powering Windsurf Tab, designed for fast, passive code prediction, now unlimited to all free and paid users.
Powered by Flow Awareness
SWE-1 was made possible through Windsurf's core design principle: flow awareness, the ability for humans and AI to operate on a shared timeline. This deep integration between the Windsurf Editor and its models allows seamless, context-aware collaboration and sets the foundation for continuously improving model performance at scale.
'Flow awareness lets us see exactly where models succeed or fail, down to the individual decision point. That feedback loop is our competitive edge,' said Anshul Ramachandran, Founding Team.
With a continuous stream of user feedback, Windsurf has been steadily building the richest representation of a shared timeline for software engineering work. SWE-1 is the initial proof of concept for understanding a true end-to-end timeline.
What's next
While SWE-1 represents Windsurf's first venture into frontier model development, it won't be the last, and it is a testament to what can be achieved with a small engineering team and a limited scope of compute. The company plans to invest aggressively in SWE models and intends on rapidly expanding its machine learning research team going forward.
Developers can begin using the SWE-1 model family with the Windsurf Editor by visiting windsurf.com today.
About Windsurf:
Windsurf is a generative AI-powered software development platform helping engineers move faster, reduce technical debt, and build with greater confidence. With code-native models and flow-aware tools, Windsurf integrates seamlessly into existing workflows to enable higher-quality engineering at scale.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ABL Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm
ABL Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm

Business Wire

time7 hours ago

  • Business Wire

ABL Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abacus Global Management, Inc. ('Abacus' or 'the Company') (NASDAQ: ABL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Abacus is the subject of a report issued by Morpheus Research on June 4, 2025, titled: 'Abacus Global Management: This $794 Million SPAC Is Yet Another Life Settlements Accounting Scheme Manufacturing Fake Revenue by Systematically Underestimating When People Will Die.' According to the report, the Company changed its portfolio valuation methodology to make it appear more profitable than it actually is. The report also alleges that the Company uses unusual methodologies to calculate life expectancy estimates and its co-founders have 'red flags' in their past. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Why Recursion Pharmaceuticals (RXRX) Soared On Friday
Why Recursion Pharmaceuticals (RXRX) Soared On Friday

Yahoo

time8 hours ago

  • Yahoo

Why Recursion Pharmaceuticals (RXRX) Soared On Friday

We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Why Recursion Pharmaceuticals (RXRX) Soared On Friday
Why Recursion Pharmaceuticals (RXRX) Soared On Friday

Yahoo

time8 hours ago

  • Yahoo

Why Recursion Pharmaceuticals (RXRX) Soared On Friday

We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store